---
schema_version: "secwatch.filing_event.v1"
accession: "0001787306-21-000029"
form_type: "8-K"
ticker: "ARQT"
cik: "0001787306"
company_name: "Arcutis Biotherapeutics, Inc."
filed_at: "2021-11-04T23:59:59+00:00"
generated_at: "2026-06-28T13:15:26.603458+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Arcutis reports Q3 net loss $57M; submits NDA for roflumilast cream in plaque psoriasis

## Summary
- Net loss of $57.0M ($1.14/sh) vs $38.2M ($1.01/sh) in Q3 2020; cash $368.8M.
- Submitted NDA to FDA for roflumilast cream for plaque psoriasis based on Phase 3 DERMIS trials.
- Initiated pivotal Phase 3 trial of roflumilast foam in scalp/body psoriasis; topline expected H2 2022.
- Terminated Phase 2a trial of ARQ-252 in vitiligo due to inadequate local drug delivery.
- R&D expense $40.6M vs $32.7M YoY; G&A expense $16.5M vs $5.6M YoY.

## SEC filing metadata
- accession: 0001787306-21-000029
- form_type: 8-K
- ticker: ARQT
- cik: 0001787306
- company_name: Arcutis Biotherapeutics, Inc.
- filed_at: 2021-11-04T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1787306/000178730621000029/0001787306-21-000029-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1787306/000178730621000029/arqt-20211104.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001787306-21-000029
- JSON: https://secwatch.observer/filing/0001787306-21-000029.json
- Plain text: https://secwatch.observer/filing/0001787306-21-000029.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.